Sequenom unloads Bioscience business for $31M

Sequenom ($SQNM) sold off its Bioscience business to Agena Bioscience for $31 million. Through the deal, Agena gains access to Sequenom's MassArray System, a diagnostic tool that uses mass spectrometry to detect genetic biomarkers for cancer. Sequenom will receive up to $4 million in additional payments if MassArray meets certain regulatory and sales milestones, the company said in a statement. More

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.